Valley View, OH (PRWEB) October 25, 2011
Dr. Scott Rickert, President and CEO of the nanotechnology company Nanofilm, will speak on Growth and Collaboration in Ohio’s Nanotechnology Community, an event of the Nano-Network, to be held in Dayton, Ohio, on October 26, 2011. Dr. Rickert’s co-presenter will be Robert Geho, President of SDG, another nanotechnology enterprise. Nanofilm and SDG have a comprehensive joint development and licensing agreement to develop and commercialize nano-formulas that combine the two companies’ technologies.
“Nanotechnology is a growth industry for Ohio,” said Dr. Rickert. “The Nanofilm-SDG partnership offers an excellent model for other organizations and I look forward to sharing it with Nano-Network audience.”
The program takes place at The Engineers Club of Dayton, 110 E. Monument Ave., Dayton. Registration opens at 6PM, and the presentation begins at 6:45. There is no charge for the event, but registration is requested at http://www.polymerohio.org.
About Nanofilm (http://www.nanofilmtechnology.com). Nanofilm is a leader in nanofilm technology and self-assembling thin films for a variety of substrates and surfaces. With an in-house team of nanotechnology specialists, the company continues to leverage its rich technological strengths and core competences to capture growth opportunities in nanotechnology applications worldwide. Nanofilm is a privately held company with headquarters in Valley View, Ohio, near Cleveland.
About the Nano-Network (http://thenanonetwork.org). The Nano-Network is an Ohio based organization founded in 2003 by scientists, entrepreneurs, and financiers to improve and expand nanotechnology research and commercialization efforts in Ohio. The organization’s objective is to act as a hub for the awareness, development and commercialization of nanotechnology in Ohio.
About SDG, Inc. (http://www.sdgpharma.com). SDG, Inc. is a privately held developer of bio-nanotechnologies for use in drug delivery systems and in consumer product applications. The Company's patented systems have been used in the creation and development of novel oral delivery systems for insulin, interferon and other protein-based therapies, cell-receptor targeting of a wide variety of large and small molecule drugs and diagnostics, and consumer products ranging from hair conditioners and styling agents to skin-adhering insect repellents and sunscreens. SDG is an Equity Partner Company of the Cleveland Clinic Foundation and a resident company in the Clinic's Innovation Center.